Abstract
The level of erbB-2 expression in both the tumour tissue and serum of individuals with colorectal carcinoma is unclear. This study aims to clarify expression levels and to relate these to a range of clinicopathological parameters. Overexpression of erbB-2 was detected in 25% of patient tumour tissue and an elevation in serum concentration of the extracellular domain (ECD) of erbB-2 was detected in 10% of patients. Surprisingly, an elevated serum ECD concentration did not correlate with erbB-2 overexpression within the primary tumour, and neither tumour or serum levels of the protein correlated with any clinicopathological parameters examined. These results indicate that erbB-2 overexpression in tissue and serum are not uncommon in colorectal carcinoma, but may not be useful as predictors of disease outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 527-531 |
| Number of pages | 5 |
| Journal | Oncology Reports |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1999 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver